Table 3.
Patients in the SABINA III PCP cohort who received prescriptions for (A) SABA monotherapy and (B) SABA in addition to maintenance therapy in the 12 months before the study visit.
| Primary care (n = 1440) | |||
|---|---|---|---|
| Investigator-classified mild asthmaa (n = 743) | Investigator-classified moderate-to-severe asthmaa (n = 695) | All (n = 1440) | |
| A. Patients prescribed SABA monotherapy | |||
| Yes | 183 (24.6) | 0 (0.0) | 183 (12.7) |
| No | 560 (75.4) | 695 (100.0) | 1257 (87.3) |
| Number of canisters or inhalers per patient prescribed 12 months before the study visit | |||
| Number of patients | 180 | NA | 180 |
| Mean (SD) | 7.2 (6.1) | NA | 7.2 (6.1) |
| Median (min–max) | 6.0 (1.0–42.0) | NA | 6.0 (1.0–42.0) |
| Missing values | 3 (1.7) | NA | 3 (1.7) |
| B. Patients prescribed SABA in addition to maintenance therapy | |||
| Yes | 402 (54.1) | 386 (55.5) | 788 (54.7) |
| No | 341 (45.9) | 309 (44.5) | 652 (45.3) |
| Number of canisters or inhalers per patient prescribed 12 months before the study visit | |||
| Number of patients | 401 | 355 | 756 |
| Mean (SD) | 6.7 (4.7) | 8.1 (14.1) | 7.4 (10.3) |
| Median (min–max) | 6.0 (1.0–24.0) | 6.0 (1.0–210.0) | 6.0 (1.0–210.0) |
| Missing values | 1 (0.2) | 31 (8.0) | 32 (4.1) |
Data are presented as n (%) unless otherwise specified. aInvestigator-classified asthma severity was guided by GINA 2017 treatment steps. Investigators were guided by GINA 2017 treatment steps, either in the study protocol or via a pop-up window in the eCRF.
eCRF electronic case report form, GINA Global Initiative for Asthm, max maximum, min minimum, NA not available, PCP primary care physician, SABA short-acting β2-agonist, SABINA SABA use IN Asthma, SD standard deviation.